Jump to content

GSK 299423

From Wikipedia, the free encyclopedia
GSK 299423
Names
Preferred IUPAC name
6-Methoxy-4-[2-(4-{[(2H-[1,3]oxathiolo[5,4-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)ethyl]quinoline-3-carbonitrile
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C25H27N5O2S/c1-31-20-2-3-23-22(11-20)21(17(12-26)13-29-23)6-9-30-7-4-18(5-8-30)27-14-19-10-25-24(15-28-19)32-16-33-25/h2-3,10-11,13,15,18,27H,4-9,14,16H2,1H3 checkY
    Key: NKXJSCXEAVZSMF-UHFFFAOYSA-N checkY
  • COc1ccc2c(c1)c(c(cn2)C#N)CCN3CCC(CC3)NCc4cc5c(cn4)OCS5
Properties
C25H27N5O2S
Molar mass 461.58 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
3D protein map of GSK 299423 (yellow) in complex with Staphylococcus aureus DNA gyrase (teal) and a DNA fragment (orange). From PDB: 2xcs​.

GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.[1][2][3]

No animal studies have been reported. No application has been made for human clinical trials.[citation needed]

References

[edit]
  1. ^ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria[permanent dead link]," The Wall Street Journal, August 4, 2010
  2. ^ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' Archived 2010-08-16 at the Wayback Machine" Daily Finance, August 6, 2010
  3. ^ Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. 466 (7309): 935–40. Bibcode:2010Natur.466..935B. doi:10.1038/nature09197. PMID 20686482. S2CID 205221405. (primary source)